All Deals
October 16, 2024 - Deals
Parakeet Health Secures $3 Million Seed Funding Led By Canvas Ventures And Other Investors
Parakeet Health, a San Francisco-based generative AI company focused on enhancing patient engagement for healthcare providers, has raised $3 million in Seed funding led by Canvas Ventures, with participation from CoFound Partners, StoryHouse Ventures, and notable investors such as former One Medical CEO Tom Lee, MD, and former Twitter CTO Adam Messinger. Under the leadership of CEO Jung Park, the company aims to utilize the funds to expand its team, advance its technology, and target health systems, multi-site medical practices, and large senior primary care providers associated with Medicare Advantage plans. Parakeet Health's platform employs advanced LLM technology to automate contact center tasks and manage patient communications efficiently, enabling providers to improve engagement and reduce administrative burdens.
INVESTORS: Canvas Ventures, CoFound Partners, StoryHouse Ventures, Tom Lee, MD & Adam Messinger
ROUND: Seed
AMOUNT: $3,000,000
HQ: #SanFrancisco #California
#VentureCapital #ParakeetHealth #CanvasVentures #CoFoundPartners #StoryHouseVentures #TomLeeMD #AdamMessinger #JungPark #TradedVC
More Deals
View All
Eli Lilly Acquires AtaiBeckley For Up To $3.8 Billion In Psychedelic Medicine DealEli Lilly is making its biggest move yet into psychedelic medicine through its planned acquisition of AtaiBeckley in a deal valued at up to $3.8 billion, the largest acquisition in the sector to date. The transaction centers on AtaiBeckley’s lead program, BPL-003, an intranasal 5-MeO-DMT therapy for treatment-resistant depression that is advancing into Phase 3 trials, along with a second DMT-based candidate in development. Founder Christian Angermayer said the focus is now on getting these therapies “into the hands of millions of patients around the globe as quickly as possible.” The deal reflects growing investor and pharmaceutical interest in psychedelic-based mental health treatments, following recent acquisitions by AbbVie and Otsuka as clinical evidence and policy support continue to strengthen across the field.
SALE PRICE: $3,800,000,000
#VentureCapital #EliLilly #AtaiBeckley #TradedVC
Tempus AI Acquires Personalis In $1.5 Billion All-Stock TransactionTempus AI announced a definitive agreement to acquire Personalis in an all-stock transaction valued at approximately $1.5 billion in enterprise value, bringing together two longtime partners in cancer monitoring and precision oncology. The acquisition builds on a collaboration that began in 2023 and expanded through Tempus’ strategic investment and exclusive commercialization partnership for Personalis’ NeXT Personal MRD test, which detects molecular residual disease and helps monitor cancer recurrence. Under the agreement, Personalis shareholders will receive $16.25 per share, representing a 6% premium to the company’s recent closing price. Personalis CEO Chris Hall said the deal offers the greatest value to shareholders and accelerates access to the company’s cancer testing technologies. The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals.
SALE PRICE: $1,500,000,000
HQ: Chicago, Illinois
#VentureCapital #TempusAI #Personalis #TradedVC
Neo Secures $100 Million Funding Led By Andreessen Horowitz And Bessemer Venture PartnersNeo, a Boston-based cybersecurity startup focused on securing AI agents and agentic software, has emerged from stealth with $100 million in total funding, including a $75 million Series A led by Andreessen Horowitz and Bessemer Venture Partners, alongside participation from Craft Ventures and Merlin Ventures, following a previously undisclosed $25 million seed round. Founded by Nick Warner, Shlomi Salem, and Eran Shirazi, Neo provides SecOps teams with real-time inventory, risk intelligence, attribution, and policy controls to govern AI agents operating across enterprise environments. The company plans to use the funding to expand its engineering and go-to-market teams as demand grows for tools that help organizations manage the security risks posed by increasingly autonomous AI systems.
FOUNDERS: Nick Warner, Shlomi Salem & Eran Shirazi
INVESTORS: Andreessen Horowitz, Bessemer Venture Partners, Craft Ventures & Merlin Ventures
ROUND: Seed + Series A
AMOUNT: $100,000,000
HQ: Boston, Massachusetts
#VentureCapital #Neo #TradedPartner #AndreessenHorowitz #TradedVC
Brookfield Asset Management And CPP Investments Acquire LXP Industrial Trust For $5.2 BillionBrookfield Asset Management and Canada Pension Plan Investment Board (CPP Investments) have agreed to acquire LXP Industrial Trust in an all-cash transaction valued at approximately $5.2 billion, including net debt and preferred equity, taking the industrial REIT private upon closing. Under the deal, LXP shareholders will receive $61.20 per share in cash, representing significant premiums to the company’s recent trading averages. LXP owns a portfolio of roughly 53 million square feet of warehouse and logistics properties across key U.S. Sunbelt and Midwest markets. LXP Chairman and CEO Thomas W. Eglin, Jr. described the transaction as the culmination of the company’s transformation into a pure-play industrial REIT, while Brookfield Real Estate CEO Lowell Baron said the acquisition aligns with Brookfield’s strategy of investing in high-quality real estate with durable cash flows and value-creation opportunities through active asset management. The transaction is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary conditions.
SALE PRICE: $5,200,000,000
#VentureCapital #BrookfieldAssetManagement #CanadaPensionPlanInvestmentBoard #LXPIndustrialTrust #TradedVC